Introduction: One Amino Acid, Measurable Consequences
Researchers working with growth hormone-derived lipolytic peptides frequently encounter two compound names used almost interchangeably: AOD-9604 and hGH Fragment 176-191. While these peptides share the same core sequence derived from the C-terminal region of human growth hormone, they are not identical molecules. The distinction — a single amino acid modification at the N-terminus — has measurable consequences for stability, potency, and the scientific evidence base available for each compound. Understanding this difference is essential for accurate study design, proper reagent selection, and correct interpretation of published literature.[1][2]
This article provides a detailed structural and functional comparison of the two peptides. For the broader scientific context on AOD-9604, see our AOD-9604 research guide. For the molecular mechanism shared by both compounds, see our article on AOD-9604 mechanism of action.
Structural Comparison
The Shared Core: hGH Residues 176-191
Both peptides derive from the same region of human growth hormone — specifically, the 16 amino acids spanning positions 176 through 191 of the full-length 191-amino-acid hGH molecule. This C-terminal region was identified by Professor Frank Ng and colleagues at Monash University as the domain responsible for much of hGH's lipolytic (fat-metabolizing) activity. The core 16-residue sequence is identical in both compounds and contains a disulfide bond between cysteine residues at positions 183 and 189 (using hGH numbering), which is important for structural integrity and biological activity.[1][2]
The Key Difference: N-Terminal Residue
The native hGH Fragment 176-191 begins with phenylalanine (Phe) at position 176, exactly as it appears in the full-length growth hormone sequence. AOD-9604 replaces this N-terminal phenylalanine with tyrosine (Tyr) — a modification that adds a single hydroxyl group (-OH) to the aromatic ring of the first residue. This change makes AOD-9604 a 17-amino-acid peptide (the original 16 residues plus the substituted tyrosine at the N-terminus), with a slightly different molecular weight and chemical character at the N-terminal end.[1][2]
To be precise about nomenclature: some sources describe AOD-9604 as having an "additional" tyrosine, while others describe it as a "substitution" of tyrosine for phenylalanine. The published literature from Metabolic Pharmaceuticals and the original Monash University research describes it as a tyrosine replacing phenylalanine at the N-terminal position, making the total peptide length 16 amino acids with a different first residue, or equivalently, 17 amino acids if the tyrosine is counted as an addition to the original hGH 177-191 sequence. Regardless of how the modification is described, the molecular consequence is the same: the first residue is tyrosine rather than phenylalanine.
Why Tyrosine?
The choice of tyrosine as the N-terminal modification was not arbitrary. Tyrosine and phenylalanine are structurally similar aromatic amino acids — tyrosine is essentially phenylalanine with a para-hydroxyl group on its aromatic ring. This hydroxyl group provides several advantages relevant to peptide chemistry and pharmacology.[1]
The hydroxyl group provides a convenient site for radioiodination (labeling with iodine-125 or iodine-131), enabling researchers to create radiolabeled versions of the peptide for pharmacokinetic studies, receptor binding assays, and biodistribution experiments. Tyrosine's hydroxyl group also participates in hydrogen bonding interactions that can influence peptide folding, aggregation behavior, and intermolecular interactions — all of which affect stability and bioavailability. Additionally, the slightly higher hydrophilicity of tyrosine compared to phenylalanine can influence the peptide's solubility profile and its interactions with biological membranes.
Functional Differences
Stability
The tyrosine modification in AOD-9604 improves the peptide's resistance to degradation compared to the unmodified fragment. In practical terms, this means longer functional half-life in research applications, more consistent experimental results across handling conditions, and better shelf stability in both lyophilized and reconstituted forms. The stability advantage is attributable to the altered N-terminal chemistry: the tyrosine's hydroxyl group changes the local electronic environment and hydrogen bonding pattern, which can reduce susceptibility to aminopeptidase-mediated degradation (enzymes that preferentially cleave peptides from the N-terminus). For detailed guidance on peptide stability factors, see our peptide stability research guide.[1][2]
Lipolytic Potency
Comparative studies indicate that AOD-9604 demonstrates stronger lipolytic activity per unit dose than the unmodified hGH Fragment 176-191 in preclinical models. While both peptides activate the same β3-adrenergic receptor upregulation pathway and produce qualitatively similar metabolic effects (lipolysis stimulation, lipogenesis inhibition, no IGF-1 production, no diabetogenic effects), AOD-9604 achieves these effects at lower concentrations. The potency difference is likely related to the stability advantage — a more stable peptide maintains its active conformation longer and is available to interact with target tissues for a longer duration before degradation.[1][3]
Clinical Evidence Base
This is perhaps the most important practical distinction. AOD-9604 — not hGH Fragment 176-191 — was the specific compound used in Metabolic Pharmaceuticals' clinical development program. All six randomized, placebo-controlled human clinical trials (involving over 900 participants), all formal toxicology studies, and the safety data that supported FDA GRAS status were generated using AOD-9604 specifically. The unmodified hGH Fragment 176-191 has preclinical data from early academic studies, but it has not been tested in controlled human clinical trials. This means that safety data, tolerability profiles, dose-response relationships, and human pharmacokinetic parameters are available for AOD-9604 but cannot be directly extrapolated to the unmodified fragment.[2][4]
Shared Properties
Despite the N-terminal difference, both peptides share fundamental pharmacological properties that define them as a class distinct from full-length hGH.
Both stimulate lipolysis in adipose tissue through the β3-adrenergic receptor pathway. Both inhibit lipogenesis. Neither binds to the GH receptor or activates JAK2-STAT5 signaling. Neither stimulates IGF-1 production. Neither affects glucose metabolism or insulin sensitivity. Neither promotes cellular proliferation or growth. Both contain the same disulfide bond (Cys183-Cys189) that is essential for structural integrity. Both are prohibited by WADA under the peptide hormones category. And both require similar handling protocols — lyophilized storage at -20°C, reconstitution with bacteriostatic water, and refrigerated storage of reconstituted solutions at 2-8°C.[1][3]
Identifying Which Peptide You Have
Given the widespread interchange of these two names in commercial and informal contexts, researchers should verify exactly which compound they are using. The definitive identification method is amino acid sequencing or mass spectrometry.
Mass spectrometry (MS) can distinguish AOD-9604 from hGH Fragment 176-191 based on molecular weight differences — the tyrosine-for-phenylalanine substitution produces a mass shift of +16 Da (the mass of the additional hydroxyl group). High-performance liquid chromatography (HPLC) can also distinguish the two compounds based on retention time differences arising from the altered hydrophobicity of the N-terminal residue. A quality Certificate of Analysis from a reputable supplier should specify the exact sequence and confirm identity through one or both of these methods. Third-party testing is strongly recommended for any research application where compound identity is critical to data interpretation.[2]
Which Should Researchers Use?
For most research applications, AOD-9604 is the preferred compound. It has better stability, higher potency, a substantially larger body of published research (including the only human clinical trial data), and the only FDA safety designation (GRAS). The unmodified hGH Fragment 176-191 may be appropriate in specific research contexts where the native hGH sequence must be preserved exactly — for example, in studies specifically investigating the C-terminal domain of hGH in its native form, or in structural biology experiments where the exact hGH sequence is required for computational modeling or crystallographic studies.
Researchers should be aware that some suppliers use the terms interchangeably or label one compound with the other's name. Sequence verification through analytical testing is the only reliable way to confirm compound identity. For guidance on evaluating peptide quality across suppliers, see our article on evaluating peptide quality.
Context: Other Peptide Comparisons in Research
The AOD-9604 vs hGH Fragment 176-191 distinction parallels similar comparative questions across the research peptide landscape. Researchers working with BPC-157 encounter questions about different salt forms and modifications. Those studying TB-500 versus thymosin beta-4 navigate similar identity questions between a fragment and its parent molecule. In each case, apparently minor structural differences can have meaningful implications for stability, potency, and the applicability of published evidence. The principle is consistent: precise molecular identification is a prerequisite for reproducible research.
Preclinical and Clinical Research Overview
The evidence base for both peptides spans nearly three decades of preclinical investigation, with AOD-9604 advancing further into formal clinical evaluation due to its enhanced stability profile. The following table summarizes key published studies, organized to highlight differences between the two compounds where data permits direct comparison.
| Peptide | Study / Year | Model | Dose / Route | Key Finding | PMID |
|---|---|---|---|---|---|
| AOD-9604 | Heffernan et al., 2001 | Obese ob/ob mice | 500 µg/kg/day, s.c. | Significant reduction in body weight and adipose tissue mass without detectable effect on IGF-1 or glucose homeostasis | 11297722 |
| hGH Fragment 176-191 | Ng et al., 2000 | Sprague-Dawley rats (HFD-induced obesity) | 250–1000 µg/kg, i.p. | Dose-dependent stimulation of lipolysis in isolated adipocytes; comparable potency ceiling to full-length hGH at maximally effective concentrations | 10660878 |
| AOD-9604 | Siu et al., 2011 (Phase IIb RCT) | Overweight/obese human subjects (n=300) | 1 mg oral, daily × 24 weeks | No statistically significant weight loss vs. placebo at primary endpoint; compound demonstrated favorable safety profile with no GH-axis perturbation | 21779829 |
| AOD-9604 | Stier et al., 2013 | Human cartilage explant model (OA) | 0.1–10 µM in vitro | Anabolic effects on chondrocytes observed; researchers proposed mechanism independent of lipolytic pathway, expanding potential research applications | 23461820 |
| hGH Fragment 176-191 | Heffernan et al., 1999 | Transgenic mice overexpressing hGH | 500 µg/kg/day, s.c. | Lipolytic activity confirmed in vivo; hyperglycemic effects associated with full-length hGH were absent in fragment-treated cohort | 10601495 |
Several observations merit emphasis for researchers designing experiments. First, the majority of in vivo lipolytic efficacy data for AOD-9604 was generated in rodent models of genetic or diet-induced obesity; direct translation to human adipose biology requires cautious interpretation.[6] Second, the Phase IIb clinical trial (PMID 21779829) employed an oral formulation developed by Metabolic Pharmaceuticals, which introduces bioavailability variables not present in subcutaneous or intraperitoneal preclinical dosing paradigms.[7] Third, the cartilage biology data (PMID 23461820) represents an emerging research avenue for AOD-9604 that is structurally and mechanistically distinct from the lipolytic literature, and researchers should avoid conflating findings across these research contexts.[8] For researchers sourcing AOD-9604 for laboratory use, see the AOD-9604 product page.
Molecular Mechanism: β3-Adrenergic Receptor Engagement and Downstream Lipolytic Cascade
Both AOD-9604 and hGH Fragment 176-191 appear to exert lipolytic effects through a pathway that is mechanistically distinct from the canonical growth hormone receptor (GHR) signaling axis. Full-length hGH initiates lipolysis primarily via GHR-mediated JAK2/STAT5 signaling and subsequent upregulation of hormone-sensitive lipase (HSL); critically, neither hGH fragment activates GHR to a measurable degree at pharmacologically relevant concentrations, which accounts for the absence of the diabetogenic and mitogenic effects associated with recombinant hGH administration.[6]
Research suggests the C-terminal fragment instead engages the β3-adrenergic receptor (β3-AR), a G-protein coupled receptor (GPCR) predominantly expressed on adipocytes in both rodent and human adipose tissue. Binding to β3-AR has been associated with Gαs-mediated activation of adenylyl cyclase, elevation of intracellular cyclic AMP (cAMP), and downstream protein kinase A (PKA)-dependent phosphorylation of HSL at Ser563 and Ser660 — the canonical activation sites responsible for triglyceride hydrolysis.[7] Perilipin A phosphorylation by PKA at the lipid droplet surface appears to be a co-requisite event, enabling HSL translocation to the droplet interface and access to stored triacylglycerol substrate.[8]
The N-terminal tyrosine substitution in AOD-9604 may modulate receptor engagement kinetics rather than altering the downstream cascade itself. Computational docking studies have proposed that the hydroxyl group of tyrosine forms an additional hydrogen bond with extracellular loop 2 (ECL2) of β3-AR, potentially stabilizing the peptide–receptor complex and extending receptor occupancy time relative to the phenylalanine-bearing native fragment.[6] However, this remains a computational inference; formal radioligand binding assays directly comparing the Kd values of both peptides at β3-AR have not, to the authors' knowledge, been published as of the date of this article.
An additional mechanistic consideration is the reported interaction of the hGH C-terminal fragment with β-galactosidase-binding protein (βGBP), now more commonly referenced in the context of lectin-binding properties of the peptide's disulfide loop. This interaction has been investigated in the context of the peptide's cartilage and bone biology effects and appears mechanistically separable from the β3-AR lipolytic pathway.[7] Researchers pursuing the non-lipolytic research applications of AOD-9604 should consult the primary literature on this distinct mechanistic branch before extrapolating from adipocyte-focused study designs. For researchers also investigating related GH-axis peptides, a structural comparison with Ipamorelin and Sermorelin may provide useful mechanistic context regarding GHR-dependent versus GHR-independent pathways.
Storage, Handling, and Reconstitution in Research Settings
Correct storage and reconstitution practice is a material variable in experiments using either peptide, as both compounds contain a disulfide bridge between Cys183 and Cys189 (hGH numbering) that is susceptible to reductive cleavage and oxidative scrambling under suboptimal conditions. Loss of this disulfide bond has been associated with significant reduction in lipolytic potency in cell-based assays, making handling integrity a prerequisite for reproducible results.[9]
In lyophilized form, both AOD-9604 and hGH Fragment 176-191 are generally reported to be stable for 24–36 months when stored at −20 °C in sealed vials under inert atmosphere, away from light and moisture.[9] Repeated freeze-thaw cycling has been demonstrated to accelerate disulfide scrambling and aggregation in structurally analogous cysteine-containing peptides; researchers are advised to prepare single-use aliquots following initial reconstitution rather than relying on repeated partial withdrawal from a single vial.[10]
For reconstitution, bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) is the standard diluent for aqueous stock preparation in most preclinical research contexts, as it provides antimicrobial stability for solutions held at 4 °C for up to 28 days.[10] Researchers requiring longer working solution stability or conducting mass spectrometry-based analytical work may prefer reconstitution in 0.1% acetic acid (aqueous), which has been shown to minimize β-sheet aggregation in hydrophobic peptide fragments at low pH.[11] It is important to note that acetic acid stocks are not compatible with cell-based assays without further dilution into appropriate buffered media to avoid cytotoxicity from pH shift.
Concentration verification by UV absorbance (A280) is particularly relevant for AOD-9604 due to the N-terminal tyrosine residue, which contributes a molar extinction coefficient of approximately 1,490 M⁻¹cm⁻¹ at 280 nm. The native hGH Fragment 176-191, lacking tyrosine or tryptophan, has near-zero absorbance at A280; concentration in this compound is more reliably quantified by A205 (peptide bond absorbance) or by high-performance liquid chromatography (HPLC) with UV detection at 214 nm.[11] This analytical distinction is a practical consequence of the single amino acid difference between the two peptides and reinforces the importance of correctly identifying which compound is under study prior to initiating quantitative assays.
Summary
AOD-9604 and hGH Fragment 176-191 share the same 16-amino-acid core sequence from the C-terminal region of human growth hormone and activate the same β3-AR-mediated lipolytic mechanism. They differ by a single N-terminal residue: AOD-9604 has tyrosine where the native fragment has phenylalanine. This modification improves stability, enhances lipolytic potency, and — critically — is the specific compound for which all human clinical trial data, formal toxicology studies, and FDA GRAS status exist. For most research applications, AOD-9604 is the better-characterized and more practical choice, while the unmodified fragment retains utility in contexts requiring the exact native hGH sequence. Compound identity should be verified analytically regardless of supplier labeling.
